Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

PRIMARY OBJECTIVES: I. Assess the activity of sunitinib malate, in terms of rate of progression-free survival for ≥ 6 months and objective tumor response, in patients with recurrent or persistent leiomyosarcoma of the uterus who have received 1 or 2 prior cytotoxic therapies. II. Determine the frequency and severity of adverse events. SECONDARY OBJECTIVES: I. Determine the duration of progression-free survival and overall survival. OUTLINE: This is a multicenter study. Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for 3 years. PROJECTED ACCRUAL: A total of 44 patients will be accrued for this study.